หน่วยวิจัยคลินิกรักษ์สุขภาพ

#adult # HIV # tuberculosis # hepatitis # Treatment

ACTG 5243 (BioBanK)

Plan for Obtaining Human Biological Samples at Non-U.S. Clinical Research Sites for Currently Unspecified Genetic Analyses

Ongoing (Enrolling)

ACTG 5324 (InMIND)

A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with no Intensification or Intensification with Dolutegravir alone for the Treatment of Cognitive Impairment in HIV

Ongoing (Follow - up)

ACTG 5332

Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)

Ongoing (Follow - up)

ACTG 5360 (MINMON)

A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naïve with Evidence of Active HCV Infection: The MINMON Study

Ongoing (Follow - up)

ACTG 5375

An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination with Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Ongoing (Enrolling)

MK1439A-021  (DRIVE-AHEAD)

phase III multicenter, double-blind, randomized, active comparator-controlled clinical trial to evaluate the safety and efficacy of MK-1439A once-daily versus ATRIPLA once-daily in treatment-naïve HIV-1 infected subjects

Ongoing (Follow - up)

Neuro Fellow ID

การศึกษาการเพิ่มขึ้นของการทำงานของระบบประสาทและการรับรู้หลังจากเปลี่ยนจากยาเอฟฟาไวเรนซ์เป็นยาริวพิไวรีน ในผู้ติดเชื้อเอชไอวีผู้ใหญ่แบบสุ่มเปรียบเทียบ

Completed

START

Strategic Timing of AntiRetroviral Treatment (START)

Ongoing (Follow - up)

 

©2019 by Research Center for Infectious Diseases and Substance Use. Proudly created with Wix.com